{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T12:07:22Z","timestamp":1775736442406,"version":"3.50.1"},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,3,26]],"date-time":"2012-03-26T00:00:00Z","timestamp":1332720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> In a previous study a new hydrosoluble nail lacquer (P\u20103051) containing 8% ciclopirox (CPX) showed higher nail penetration compared to a water\u2010insoluble 5% amorolfine (MRF) lacquer. To our knowledge, <jats:italic>in vivo<\/jats:italic> human data on a similar topic are not available.<\/jats:p><jats:p><jats:bold>Objectives\u2002<\/jats:bold> To compare fingernail penetration of P\u20103051 with that of MRF reference in humans and to evaluate their predicted efficacy against <jats:italic>Trichophyton rubrum<\/jats:italic> and <jats:italic>Candida parapsilosis<\/jats:italic>.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Single centre, randomized, multiple dose, open label, within subjects study. Test and reference were self\u2010applied to all fingernails of either hand for 28\u2003days. At baseline and after 15 and 25\u2003days, the nail free edge was collected for analysis. Efficiency coefficients were calculated for <jats:italic>T. rubrum<\/jats:italic> and <jats:italic>C. parapsilosis<\/jats:italic> as ratios of nail concentration\/minimum inhibitory concentration. The coefficients were classified as very high, high or poor.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Nail concentrations after 15\u2003days were 2.82\u2003\u00b1\u20030.58\u2003\u03bcg\/mg for CPX and 0.64\u2003\u00b1\u20030.11\u2003\u03bcg\/mg for MRF. At day 25 there was a non\u2010significant decline (1.85\u2003\u00b1\u20030.31\u2003\u03bcg\/mg, <jats:italic>P\u2003<\/jats:italic>=\u20030.077) for CPX and a highly significant (0.13 \u2003\u00b1\u20030.03\u2003\u03bcg\/mg, <jats:italic>P\u2003<\/jats:italic>=\u20030.0002) 80% decline for MRF. Efficiency coefficients were very high\/high in all subjects treated with P\u20103051 against both <jats:italic>T. rubrum<\/jats:italic> and <jats:italic>C. parapsilosis<\/jats:italic>; they were significantly lower for MRF reference against both pathogens at both observation points.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> P\u20103051 exhibited better penetration and higher predicted efficacy after <jats:italic>in vivo<\/jats:italic> multiple application to human fingernails when compared to MRF reference. These <jats:italic>in vivo<\/jats:italic> data are in good agreement with our previous <jats:italic>in vitro<\/jats:italic> study.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2012.04529.x","type":"journal-article","created":{"date-parts":[[2012,3,27]],"date-time":"2012-03-27T01:14:25Z","timestamp":1332810865000},"source":"Crossref","is-referenced-by-count":28,"title":["Nail penetration and predicted mycological efficacy of an innovative hydrosoluble ciclopirox nail lacquer vs. a standard amorolfine lacquer in healthy subjects"],"prefix":"10.1111","volume":"27","author":[{"given":"D.","family":"Monti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Herranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Dal Bo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Subissi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,3,26]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.00007.x"},{"key":"e_1_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05726.x"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2004.00988.x"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(03)00025-1"},{"key":"e_1_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(01)00989-9"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/00015550410018361"},{"key":"e_1_2_10_8_2","first-page":"3","article-title":"Hepatic reactions with terbinafine","volume":"27","author":"Topliss D","year":"2008","journal-title":"Aust Adverse Drug React Bull"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2007.tb01313.x"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1081\/DDC-43935"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03164.x"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09504.x"},{"key":"e_1_2_10_13_2","unstructured":"MaillandF BaranR CaseriniM.Pharmacokinetic\/pharmacodynamic relationship of a new nail lacquer in the treatment of onychomycosis. Proceedings 6th EADV Spring Symposium Bucharest 23\u201326 April 2009"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0926-9959(94)00075-B"},{"key":"e_1_2_10_15_2","unstructured":"Guideline on the investigation of bioequivalence. CPMP\/QWP\/EWP\/1401\/98 Rev. 1 20 January2010."},{"key":"e_1_2_10_16_2","unstructured":"Guidance for Industry Skin Irritation and Sensitization Testing of Generic Transdermal Drug Products FDA CDER February 1999 OGD."},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200607040-00007"},{"key":"e_1_2_10_18_2","first-page":"604","article-title":"Different physicochemical properties of antimycotic agents are relevant for penetration into and through human nails","volume":"61","author":"Neubert RH","year":"2006","journal-title":"Pharmazie"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1992.tb00273.x"},{"key":"e_1_2_10_20_2","doi-asserted-by":"publisher","DOI":"10.1159\/000247611"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1992.tb00270.x"},{"key":"e_1_2_10_22_2","first-page":"1303","article-title":"Topical delivery of antifungal Agents Expert Opin","volume":"7","author":"Kaur IP","year":"2010","journal-title":"Drug Deliv"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.109072"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.109071"},{"key":"e_1_2_10_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10303.x"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2012.04529.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2012.04529.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T11:11:45Z","timestamp":1697368305000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2012.04529.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,26]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1111\/j.1468-3083.2012.04529.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04529.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,26]]}}}